


Yp537 TFA

Cat. No.:	HY-P3833A
Molecular Formula:	C ₆₆ H ₁₀₅ F ₃ N ₁₃ O ₂₄ PS
Molecular Weight:	1584.65
Sequence:	Cys-Asn-Val-Val-Pro-Leu-{Tyr(PO3H2)}-Asp-Leu-Leu-Leu-Glu
Sequence Shortening:	CNVVPL-{Tyr(PO3H2)}-DLLLE
Target:	Estrogen Receptor/ERR
Pathway:	Vitamin D Related/Nuclear Receptor
Storage:	Sealed storage, away from moisture and light, under nitrogen
	Powder -80°C 2 years
	-20°C 1 year



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

SOLVENT & SOLUBILITY

In Vitro

H₂O : 9.09 mg/mL (5.74 mM; ultrasonic and adjust pH to 8 with NaOH)

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		Concentration			
	1 mM		0.6311 mL	3.1553 mL	6.3105 mL
	5 mM		0.1262 mL	0.6311 mL	1.2621 mL
	10 mM		---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Yp537 TFA is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor^[1].

In Vitro

Yp537 TFA (5-50 μM; 1 h) abolishes the formation of the hER-ERE complex. And dose not inhibit the formation of the STAT1-serum-induced element complex^[1].

Yp537 TFA binds to a SH2-like domain, and interferes with the SH2-like phosphopeptide coupling mechanism between hER monomers^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Arnold SF, et al. An antiestrogen: a phosphotyrosyl peptide that blocks dimerization of the human estrogen receptor. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7475-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA